Technical Program
Technical Program
...
Technical Program
(this program is subject to change)
| Day 1 - October 28, 2024 | ||
| Start Time | End Time | |
| 8:30 AM | 9:30 AM | Registration (open all day) |
| 9:30 AM | 9:40 AM | Morning Welcome |
| 9:40 AM | 10:50 AM | Session 1 - Advances in Cellular Immunotherapy |
| 9:40 AM | 10:10 AM | Umoja's Make vs Buy decision: Managing internal risks and speed to commercialization of an owned approach versus CDMO for a pre-clinical cell & gene therapy biotech Ryan Crisman - Umoja Biopharma |
| 10:10 AM | 10:30 AM | Optimized Drug Combinations Generate Robust Human Tolerogenic Dendritic Cells Peter Deak - Drexel University |
| 10:30 AM | 10:50 AM | Human iPSC Genome Engineering at 100+ Kilobases for Universal-Donor Cell Therapies Sarah Levovitz - New York University |
| 10:50 AM | 11:20 AM | Coffee Break |
| 11:20 AM | 12:30 PM | Session 2 - Cell Biology and Engineering |
| 11:20 AM | 11:50 AM | Human Trophoblast Stem Cells to Accelerate Cell Therapies & Immunotherapies Yuta Lee - Accelerated Bio |
| 11:50 AM | 12:10 PM | Synthetic Manipulation of Hepatocyte Cell State for Expandable and Functional Liver Tissue Implants Amy Stoddard - Massachussetts Institute of Technology |
| 12:10 PM | 12:30 PM | Enzymatically-Degradable Hydrogel Microcarriers and Pro-Inflammatory Cytokine Licensing Modulate Mesenchymal Stromal Cell Secretome Keshav Shah - Georgia Institute of Technology |
| 12:30 PM | 2:00 PM | Lunch |
| 2:00 PM | 2:50 PM | Session 3 - Advances in Cell Therapy Platforms |
| 2:00 PM | 2:30 PM | NEX-T® Generation of Autologous CAR T Cell Process Development: NEX-T® CD19 Platform Process Overview Divya Varun - Bristol Myers Squibb |
| 2:30 PM | 2:50 PM | Synziftr 2.0: Expanding Clinical Potential of Synthetic Gene Circuits for Advanced Cell Therapies with Novel Transcriptional Activation Domain (TAD) Architectures Hanrong Ye - Boston University |
| 2:50 PM | 3:20 PM | Afternoon Coffee Break |
| 3:20 PM | 4:10 PM | Session 4 - Poster Lightning Talks |
| 4:10 PM | 4:15 PM | First Day Closing |
| Day 2 - October 29, 2024 | ||
| 8:30 AM | 9:30 AM | Registration (open all day) |
| 9:30 AM | 9:40 AM | Morning Welcome |
| 9:40 AM | 10:30 AM | Keynote: 40 Years of Cell Adaptation To Cell Culture Bioreactors: The Key to Success for CHO and Cell Therapies? Matt Croughan - PBS Biotech |
| 10:30 AM | 11:00 AM | Morning Coffee Break |
| 11:00 AM | 12:20 PM | Session 5 - Advances in CAR Cell Therapies |
| 11:00 AM | 11:30 AM | Exploring Novel CAR T-Cell Therapies for AML Paulina Velasquez - St. Jude Children’s Research Hospital |
| 11:30 AM | 11:50 AM | In Situ CAR-T Cell Programming Via Local Iontophoretic Delivery of mRNA Nanocarriers to Solid Tumors and the Spleen Jihyun (Luna) Hwang - Stanford University |
| 11:50 AM | 12:20 PM | Trains: A Novel Gene Delivery Platform for Engineering CAR NK Cells in Cancer Immunotherapy Amy Laturski - Stanford University |
| 12:20 PM | 1:45 PM | Lunch |
| 1:45 PM | 2:35 PM | Session 6 - Manufacturing and Process Analytics I |
| 1:45 PM | 2:15 PM | Process Systems Engineering in Precision Medicine: Autologous Cell & Gene Therapy B. Wayne Bequette - Rensselaer Polytechnic Institute |
| 2:15 PM | 2:35 PM | Systematic Analysis of Inherent Dose Uncertainty in Cell Therapy Products Sangwook Choi - Bristol Myers Squibb |
| 2:35 PM | 3:05 PM | Afternoon Coffee Break |
| 3:05 PM | 4:45 PM | Session 7 - Poster Presentations |
| Day 3 - October 30, 2024 | ||
| 8:30 AM | 9:30 AM | Registration (open all day) |
| 9:30 AM | 9:40 AM | Morning Welcome |
| 9:40 AM | 10:30 AM | Keynote: Neurons from stem cells to treat neurodegenerative disease Jeanne Loring - Scripps Research |
| 10:30 AM | 11:00 AM | Morning Coffee Break |
| 11:00 AM | 12:20 PM | Session 8 - Manufacturing and Process Analytics II |
| 11:00 AM | 11:30 AM | The impact of short manufacturing process couples with NGS based QC release on Autologous Cell Therapies Eytan Abraham - Resilience |
| 11:30 AM | 12:00 PM | Advances in Cellular Immunotherapy/Manufacturing and Process Analytics - Challenges and Opportunities Alan Smith - Charles River Laboratories |
| 12:00 PM | 12:20 PM | Enabling Allogeneic-based Cell Therapies Inbar Friedrich Ben-Nun - Lonza |
| 12:20 PM | 12:30 PM | Closing Statements |
